Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension
ÖGH · 2024 · Austria
Source and licence
- Authors
- David Zweiker, Christian Koppelstätter, Katharina Hohenstein et al.
- Title
- Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension
- Journal
- Wiener Klinische Wochenschrift, 2024
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC11420322
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
Verbatim, with grade of recommendation or strength of consensus where given.
Procedural planning and patient preparation
- We recommend the establishment of a standard operating procedure that includes acute management in case of complications.
Abstract
Renal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient selection and follow-up, recent randomized sham-controlled trials of second-generation devices show a consistent blood pressure lowering effect of RDN, as compared to sham controls. These new data and the recent U.S. Food and Drug Administration (FDA) premarket approval of two RDN devices are the basis for the present recommendations update.
This joint position paper from the Austrian Society of Hypertension, together with the Austrian Society of Nephrology and the Working Group of Interventional Cardiology from the Austrian Society of Cardiology includes an overview about the available evidence on RDN and gives specific recommendations for the work-up, patient selection, pretreatment, procedural management and follow-up in patients undergoing RDN in Austria. Specifically, RDN may be used in clinical routine care, together with lifestyle measures and antihypertensive drugs, in patients with resistant hypertension (i.e. uncontrolled blood pressure on 3 antihypertensive drugs) and in those with uncontrolled hypertension, after adequate work-up, if institutional, patient-related and procedural conditions are fulfilled.
Contents of the original publication
The section headings of the original.
- Introduction
- History of RDN
- Methods of RDN
- Safety
- Efficacy of RDN
- Center qualification
- Multidisciplinary hypertension team (MDT)
- RDN operators
- Patient selection
- Adherence to medical treatment
- Screening for RDN and shared decision making
- Resistant hypertension
- Mild hypertension
- Uncontrolled hypertension with intolerance to antihypertensive drugs
- Current European Society of Hypertension guidelines
- Predictor of response to RDN
- When not to perform RDN
- Procedural considerations
- Procedural planning and patient preparation
- Procedure
- Follow-up and quality control
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint